NCT02610582View on ClinicalTrials.gov

Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Achromatopsia
Interventions
DRUG

rAAV.hCNGA3

Single subretinal injection of rAAV.hCNGA3

Trial Locations (1)

72076

University Hospital Tuebingen, Center for Ophthalmology, Tübingen

All Listed Sponsors
collaborator

University Hospital Tuebingen

OTHER

collaborator

Ludwig-Maximilians - University of Munich

OTHER

lead

STZ eyetrial

OTHER

NCT02610582 - Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia | Biotech Hunter | Biotech Hunter